Attorneys General Support The Public Safety Officer Act of 2022

April 25, 2022

NAAG is urging Congress to pass The Public Safety Officer Support Act of 2022. The legislation addresses gaps in support for public safety officers who suffer from post-traumatic stress disorder (PTSD) associated with the high-risk nature of their jobs. In the letter signed by 53 attorneys general, the attorneys general praise the work of public…

Read More →

Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)

October 9, 2020

Plaintiff states settled with drug maker Organon USA, Inc. and its parent company, Akzo Nobel N.V., resolving antitrust claims involving the antidepressant drug Remeron between June 2001 and October 2004. The states’ complaint alleged that Organon unlawfully extended its monopoly by improperly listing a new “combination therapy” patent with the U.S. Federal Drug Administration. In addition, the complaint alleged that Organon delayed listing the patent with the FDA in another effort to delay the availability of lower-cost generic substitutes. The $26 million settlement resolved claims brought by state attorneys general, as well as a private class action brought on behalf of a class of end payors. Organon also agreed to make timely listings of patents and to submit accurate and truthful information to the FDA.

Read More →

Ohio, et al, v. Bristol-Myers Squibb Co., et al.(D.D.C. 2002); see also In re Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.)

October 9, 2020

Plaintiff States sought damages and injunctive relief, alleging that the drug company, Bristol-Myers Squibb, Co. (BMS) wrongfully maintained a monopoly on Taxol, a drug for which the Plaintiff States alleged Defendant fraudulently filed a patent. BMS’s alleged wrongful action delayed entry into the market by generic competitors of the drug, resulting in higher prices for Taxol. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlemen, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.

Read More →

Florida, et al. v. Nine West Group, Inc. and John Doe, 1-500, 80 F. Supp.2d 181 (S.D.N.Y. 2000); No. 00-CV-1707 (S.D.N.Y. Dec. 14, 2000)

October 9, 2020

Plaintiff States sought damages and injunctive relief, alleging that Nine West Group (Nine West) conspired with unnamed dealers to set the minimum resale price at
which retailers were permitted to sell women’s dress shoes to customers.

Read More →

NAAG to Congress: Reauthorize Violence Against Women Act

October 7, 2020

As the legislative history of VAWA has shown, members from both sides of the aisle have come together to strengthen existing protections and fill gaps in the law. We, therefore, urge you to work together as leaders of your respective caucuses and committees to act before VAWA expires and pass a VAWA reauthorization bill that continues to ensure our nation’s most vulnerable victims are not left behind.

Read More →